WallStreetZenWallStreetZen

NASDAQ: REUN
Reunion Neuroscience Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for REUN

Based on 3 analysts offering 12 month price targets for Reunion Neuroscience Inc.
Min Forecast
$5.00+354.55%
Avg Forecast
$12.00+990.91%
Max Forecast
$20.00+1,718.18%

Should I buy or sell REUN stock?

Based on 3 analysts offering ratings for Reunion Neuroscience Inc.
Strong Buy
Strong Buy
2 analysts 66.67%
Buy
1 analysts 33.33%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their REUN stock forecasts and price targets.

REUN stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
ThinkEquity
Top 42%
59
Strong BuyInitiates Coverage On$5.00+354.55%2023-05-01
HC Wainwright & Co.
Bottom 1%
1
BuyReiterates$20.00+1,718.18%2023-02-15
EF Hutton
Bottom 4%
4
Strong BuyReiterates$11.00+900.00%2023-02-14

1 of 1

Forecast return on equity

Is REUN forecast to generate an efficient return?
Company
-126.97%
Industry
-0.01%
Market
71.96%
REUN's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is REUN forecast to generate an efficient return on assets?
Company
-92.66%
Industry
-0.01%
REUN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

REUN revenue growth forecast

How is REUN forecast to perform vs Medical Care Facilities companies and vs the US market?
Company
297.58%
Industry
6.27%
Market
8.43%
REUN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
REUN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

REUN vs Medical Care Facility Stocks

TickerPricePrice TargetUp/downsideConsensus
REUN$1.10$12.00+990.91%Strong Buy
OTRK$0.46N/AN/A
AMS$2.86N/AN/A
NVOS$0.13N/AN/A
SSY$0.98N/AN/A
View Top Medical Care Facility Stocks

Reunion Neuroscience Stock Forecast FAQ

Is Reunion Neuroscience Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: REUN) stock is to Strong Buy REUN stock.

Out of 3 analysts, 2 (66.67%) are recommending REUN as a Strong Buy, 1 (33.33%) are recommending REUN as a Buy, 0 (0%) are recommending REUN as a Hold, 0 (0%) are recommending REUN as a Sell, and 0 (0%) are recommending REUN as a Strong Sell.

If you're new to stock investing, here's how to buy Reunion Neuroscience stock.

What is REUN's forecast return on equity (ROE) for 2024-2026?

(NASDAQ: REUN) forecast ROE is -126.97%, which is considered weak.

What is REUN's Price Target?

According to 3 Wall Street analysts that have issued a 1 year REUN price target, the average REUN price target is $12.00, with the highest REUN stock price forecast at $20.00 and the lowest REUN stock price forecast at $5.00.

On average, Wall Street analysts predict that Reunion Neuroscience's share price could reach $12.00 by May 1, 2024. The average Reunion Neuroscience stock price prediction forecasts a potential upside of 990.91% from the current REUN share price of $1.10.

What is REUN's forecast return on assets (ROA) for 2024-2026?

(NASDAQ: REUN) forecast ROA is -92.66%, which is lower than the forecast US Medical Care Facilities industry average of -0.01%.
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTube
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.